

HR 1703

Medical Product Communications Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 23, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 24, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/1703>

Sponsor

Name: Rep. Griffith, H. Morgan [R-VA-9]

Party: Republican • State: VA • Chamber: House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		Jun 2, 2017

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 24, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Mar 23, 2017)

Medical Product Communications Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to state that the intended use of a drug, biological product, or device shall be determined by the objective intent of the manufacturer and sponsor of such drug, biological product, or device, as demonstrated by statements contained in labeling, advertising, or analogous oral statements.

The intended use of these medical products shall not be determined by actual or constructive knowledge of the manufacturer or sponsor that these products will be used in a manner that varies from the use approved for marketing.

Additionally, the scientific exchange of information about these products shall not constitute labeling, advertising, or evidence of a new intended use. The bill sets forth the requirements for a scientific exchange.

## Actions Timeline

---

- **Mar 24, 2017:** Referred to the Subcommittee on Health.
- **Mar 23, 2017:** Introduced in House
- **Mar 23, 2017:** Referred to the House Committee on Energy and Commerce.